Patient Square Capital LP Buys New Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Patient Square Capital LP bought a new stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) in the third quarter, HoldingsChannel.com reports. The institutional investor bought 39,422 shares of the biotechnology company’s stock, valued at approximately $434,000. Astria Therapeutics comprises approximately 0.2% of Patient Square Capital LP’s investment portfolio, making the stock its 11th largest position.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ATXS. FMR LLC lifted its holdings in Astria Therapeutics by 29.2% in the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after acquiring an additional 1,767,714 shares during the period. Vestal Point Capital LP grew its holdings in Astria Therapeutics by 23.1% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after buying an additional 750,000 shares in the last quarter. Nantahala Capital Management LLC purchased a new position in Astria Therapeutics during the 2nd quarter valued at approximately $6,142,000. Vanguard Group Inc. grew its holdings in Astria Therapeutics by 23.4% during the 1st quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock valued at $35,693,000 after buying an additional 480,184 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in Astria Therapeutics during the 2nd quarter valued at approximately $2,561,000. Institutional investors own 98.98% of the company’s stock.

Analyst Upgrades and Downgrades

ATXS has been the subject of a number of research analyst reports. Oppenheimer raised their price target on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Wedbush reiterated an “outperform” rating and issued a $22.00 target price on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a report on Thursday, November 14th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $25.60.

Astria Therapeutics Trading Down 1.4 %

Shares of ATXS opened at $10.23 on Wednesday. The company’s 50 day simple moving average is $11.02 and its 200-day simple moving average is $10.65. Astria Therapeutics, Inc. has a 12-month low of $4.67 and a 12-month high of $16.90. The firm has a market cap of $577.28 million, a PE ratio of -4.89 and a beta of 0.67.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.